Nektar Therapeutics (NKTR) Tops Q1 EPS Views
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $70.67 -1.09%
Revenue Growth %: -7.1%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
HFBL, PBHC, PBNK, More
Revenue Growth %: -7.1%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
HFBL, PBHC, PBNK, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of $0.25, $0.65 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $108.8 million versus the consensus estimate of $20.2 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Investing.com’s stocks of the week
- Granite Construction (GVA) Misses Q2 EPS by 10c
- Home Federal Bancorp of Louisiana (HFBL) Tops Q2 EPS by 46c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
